{
  "id": "6023501a1cb411341a000096",
  "type": "factoid",
  "question": "What is the generic name of the Xofluza?",
  "ideal_answer": "Baloxavir marboxi is the generic name of Xofluza. It is approved for influenza.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33497124",
    "http://www.ncbi.nlm.nih.gov/pubmed/30852344",
    "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
    "http://www.ncbi.nlm.nih.gov/pubmed/32601915",
    "http://www.ncbi.nlm.nih.gov/pubmed/30766008",
    "http://www.ncbi.nlm.nih.gov/pubmed/30710642",
    "http://www.ncbi.nlm.nih.gov/pubmed/30983160",
    "http://www.ncbi.nlm.nih.gov/pubmed/34348638"
  ],
  "snippets": [
    {
      "text": "Baloxavir marboxil (Xofluza\u00ae; hereafter referred to as baloxavir), the prodrug of baloxavir acid, is a first-in-class, small molecule inhibitor of the polymerase acidic (PA) protein subunit of the influenza virus polymerase complex.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32601915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Xofluza (baloxavir marboxil) for influenza approved in Japan under the SAKIGAKE Designation System is a good example of clinical trials including Japan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30710642",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Arikayce (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease; Xofluza (baloxavir marboxil) for acute uncomplicated influenza; and Nuzyra (omadacycline) for community-acquired bacterial pneumonia and/or acute bacterial skin and skin structure infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30766008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The latest approved antiviral is baloxavir marboxil (trade name, Xofluza) which targets the endonuclease function of the viral PA polymerase subunit and prevents the transcription of viral mRNA. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30852344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baloxavir marboxil (Xofluza\u00ae), recently approved for clinical use, inhibits cap-snatching endonuclease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The latest approved antiviral is baloxavir marboxil (trade name, Xofluza) which targets the endonuclease function of the viral PA polymerase subunit and prevents the transcription of viral mRNA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30852344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baloxavir marboxil (Xofluza\u00ae; hereafter referred to as baloxavir), the prodrug of baloxavir acid, is a first-in-class, small molecule inhibitor of the polymerase acidic (PA) protein subunit of the influenza virus polymerase complex. Bal",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32601915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he latest approved antiviral is baloxavir marboxil (trade name, Xofluza) which targets the endonuclease function of the viral PA polymerase subunit and prevents the transcription of viral mRNA. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30852344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baloxavir marboxil (Xofluza\u2122; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "se, from the innovation of to begin with antiviral medicate Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was FDA-approved in 2018, the hone of creating antivirals has changed significantly. In this art",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348638",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Arikayce (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease; Xofluza (baloxavir marboxil) for acute uncomplicated influenza; and Nuzyra (omadacycline) for community-acquired bacterial pneumonia and/or acute bacterial skin and skin struc",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30766008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baloxavir marboxil (Xofluza), an antiviral flu treatment, has now been approved to prevent influenza.Pa",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33497124",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baloxavir marboxil (Xofluza), an antiviral flu treatment, has now been approved to prevent influenza.Patients should avoid taking calcium, aluminum, or magnesium products while receiving baloxavir as this will lead to a loss of antiviral efficacy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33497124",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In any case, from the innovation of to begin with antiviral medicate Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was FDA-approved in 2018, the hone of creating antivirals has changed significantly.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348638",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Baloxavir marboxi"
}